PHAT · Phathom Pharmaceuticals, Inc.
$6.15
+0.16 (+2.67%)
At close · Oct 28
Return incl. dividend (before tax)
Market Cap
$484.60M
Shares
80.90M
Volume · Oct 28
885.68K
Avg daily vol (3M)
1.49M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.99
Open$5.91
Day$5.81–6.18
52W close$5.74–18.08
Avg vol 30d1.5M
Short int9.8M · 12.1% float · 6.9d
Short vol41%
Last earningsOct 29, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 29, 2026
Scheduled
· this week
call held Jul 30, 2026
Latest filings
8-K
Other events
·
filed Oct 26, 2026
Phathom Pharmaceuticals, Inc. said the FDA opened Docket No. FDA-2026-N-13038 to solicit comments on litigation challenging VOQUEZNA’s 10 years of NCE exclusivity through May 3, 2032. Comments are due November 23, 2026.
Read the 8-K
10-Q
filed Jul 30, 2026
Read the 10-Q
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$239.66M
Trailing 12 months
Net income (TTM)
−$99.07M
Trailing 12 months
Revenue growth YoY
+88.0%
Year over year
Operating margin
-17.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$17.89M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.6%
Year over year · more shares
Price change (1Y)
-56.6%
Trailing year
Short interest
12.1%
Latest settlement · 6.9 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.5 · elevated
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−23%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
2%
near low
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−53%
trailing
YTD return
−64%
this year
Relative strength
−58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
22 of 163 funds reported for Sep 30 · net +1.7M sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.09% of float · ▼ -3.2% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+217%
Y/Y
Gross margin
87%
expanding
EPS growth
+43%
Y/Y
Free cash flow
$-167.0M
Balance sheet
$79.1M
net debt
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jul 30, 2026
Full year 2026 revenue
· full year 2026
Lowered
$310M – $325M
Apr 30, 2026
$320M – $345M
changed to
Jul 30, 2026
$310M – $325M
prior FY $175.11M
midpoint +81.3% Y/Y
Gross-to-net discount
· full year 2026
Maintained
55% – 59%
Apr 30, 2026
55% – 59%
changed to
Jul 30, 2026
55% – 59%
Gross margin
· full year 2026
Maintained
80%
Apr 30, 2026
80%
changed to
Jul 30, 2026
80%
Cash operating expenses excluding stock-based compensation
· full year 2026
Non-GAAP
Lowered
$235M – $245M
Apr 30, 2026
$235M – $255M
changed to
Jul 30, 2026
$235M – $245M
Previous outlook
earlier release
· from the 8-K filed Apr 30, 2026
Still-open targets the latest release did not restate under the same label.
Non-GAAP operating expenses, excluding stock-based compensation
· full year 2026
$235M – $255M
Prior guidance
period ended
· from the Earnings Call filed Oct 30, 2025
Full year revenue
· full year 2025
$170M – $175M
Operating expenses
· fourth quarter
up to $55M
Non-GAAP operating expenses
· full year 2025
$280M – $290M
Guided vs delivered
· last 1 settled
Full year revenue
full year 2025
guided $170M – $175M
$175.11M
Beat +1.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
22 of 163 funds reported for Sep 30 · net +1.7M sh shares · +4 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.09% of float · ▼ -3.2% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $6 · 2%
Range high $18
vs 200-day avg -43%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Covered prescriptions filled | 209,000 | Q2 2026 | — |
| Non-GAAP adjusted net loss non-GAAP | $0.1M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -17.58M
+6.71M Stock-based compensation expense (A)
+9.83M Non-cash interest on revenue interest financing liability
+912K Interest expense related to amortization of debt discount
= Non-GAAP adjusted net loss -130K
|
|||
| Non-GAAP operating expenses, excluding stock-based compensation non-GAAP | $56.4M | Q2 2026 | — |
| Total VOQUEZNA prescriptions filled | 325,000 | Q2 2026 | — |
| Total VOQUEZNA prescriptions filled to date | 1.7M | as of July 17, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PHAT
this stock
Phathom Pharmaceuticals, Inc.
|
$484.60M | -63.9% | +216.9% | — | 12.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.7% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 26, 2026
- This year
- 21
Phathom Pharmaceuticals, Inc. said the FDA opened Docket No. FDA-2026-N-13038 to solicit comments on litigation challenging VOQUEZNA’s 10 years of NCE exclusivity through May 3, 2032. Comments are due November 23, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PHAT | -18.1% | -18.6% | -52.7% | -18.0% | -63.9% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | -18.1% | -19.3% | -57.6% | -18.9% | -76.8% |
Key facts
CIK
1783183
CUSIP
71722W107
13F (30d)
19 filings
19 filers
Visit website
Investor relations